12th European Headache Federation Congress

28-30 September 2018
Florence
Palazzo dei Congressi
www.ehf2018.com
07:00 - 08:00  REGISTRATION

08:00 - 09:00  INDUSTRY SPONSORED SESSION - Non CME Session

09:00 - 09:30  GREPPI AWARD 2018
   Chair: P. Martelletti (Rome, Italy), F. Pierelli (Rome, Italy)
   “Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials” - D. Magis (Liège, Belgium)

09:30 - 10:30  INFLAMMATION
   Chair: R. Burstein (Boston, USA)
   Pain regulation by non-neuronal cells and inflammation – R-R Ji (Durham, USA)
   What is the evidence for role of inflammation in migraine? Why do NSAIDs work so effectively in acute treatment – M. Ashina (Copenhagen, Denmark)
   Imaging inflammation in animal models of migraine – A. Schain (Boston, USA)

10:30 - 11:00  COFFEE BREAK & e-POSTER DISCUSSION

11:00 - 12:00  ADDICTION: IS MEDICATION OVERUSE (HEADACHE) A FORM OF ADDICTION?
   Chair: Z. Katsarava (Unna, Germany)
   Neurobiology of addiction – Y. Shaham (Baltimore, USA)
   Is MO(H) a form of addiction? Is it unique to migraine patients? Why? – C. Tassorelli (Pavia, Italy)

12:00 - 13:00  COMPARING CEPHALIC AND NON-CEPHALIC PAIN IN ADOLESCENTS AND ADULTS
   Chair: M. Ashina (Copenhagen, Denmark)
   Challenging two SS’s in pain chronification – D. Borsook (Boston, USA)
   Differences and similarities observed in in functional imaging of headache studies – A. Hougaard (Copenhagen, Denmark)

13:00 - 14:00  BREAK & e-POSTER DISCUSSION

14:00 - 15:00  INDUSTRY SPONSORED SESSION - CME Accredited

15:00 - 16:00  THE COMORBID RELATIONSHIP BETWEEN MIGRAINE AND EPILEPSY
   Chair: R. Burstein (Boston, USA)
   The comorbid relationship between migraine and epilepsy. – R.B. Lipton (New York, USA)
   Is there a genetic link between migraine and epilepsy? – G. Terwindt (Leiden, The Netherlands)
   Seizure activates the trigeminovascular system differently than CSD: implications to differences between post-ictal headache and migraine – A. Melo-Carrillo (Boston, USA)
### Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:00 - 16:30 | **EMA REGULATORY SCIENCE IN MIGRAINE**  
  **Chair:** P. Martelletti (Rome, Italy)  
  Sharing medicines information in the European Medicines Agency regulatory network – J. Garcia-Burgos (London, UK)  
  The EMA-EHF Documento for migraine – P. Martelletti (Rome, Italy) |
| 16:30 - 17:30 | **OPENING CEREMONY**  
  **Chairs:** P. Martelletti (Rome, Italy), R. Burstein (Boston, USA)  
  LECTURE Fifty years of Norwegian contribute to headache research – L. Stovner (Trondheim, Norway)  
  EHF LECTURE: Targeting metabotropic glutamate receptors in the treatment of chronic pain – F. Nicoletti (Rome, Italy) |

### Sala Verde

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td><strong>EHF-SCHOOL OF ADVANCED STUDIES</strong></td>
</tr>
<tr>
<td>09:00 - 10:30</td>
<td><strong>ORAL PRESENTATIONS (N=9)</strong></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td><strong>COFFEE BREAK AND e-POSTER DISCUSSION</strong></td>
</tr>
</tbody>
</table>
| 11:00 - 12:00 | **IS MIGRAINE ASSOCIATED WITH STRUCTURAL BRAIN CHANGES?**             
  **Chair:** D. Borsook (Boston, USA)  
  MRI studies can predict progression of disease years before it occurs – R. Messina (Milan, Italy)  
  MRI studies cannot predict progression of disease years before it occurs – D. Gaist (Odense, Denmark) |
| 12:00 - 13:00 | **ORAL PRESENTATIONS (N=6)**                                          |
| 13:00 - 14:00 | **BREAK & e-POSTER DISCUSSION**                                       |
| 14:00 - 15:00 | **BRAINSTEM AURA**                                                    
  **Chair:** A. Ducros (Montpellier, France)  
  Brainstem aura is real – J. Olesen (Copenhagen, Denmark)  
  Brainstem aura is not real – A. Ducros (Montpellier, France) |
Saturday, 29 September 2018

Auditorium

08:00 - 08:40  **GENETIC VS ENVIRONMENTAL**  
Chair: C. Lampl (Linz, Austria)  
Migraine onset in childhood is a genetic disease – A. Hershey (Cincinnati, USA)  
Migraine in childhood is an environmental disease – V. Guidetti (Rome, Italy)

08:40 - 09:20  **OCCIPITAL HEADACHE**  
Chair: D.D. Mitsikostas (Athens, Greece)  
Occipital migraine and the cerebellum – R. Noseda (Boston, USA)  
Occipital migraine and muscle tenderness – L. Bendtsen (Copenhagen, Denmark)

09:20 - 10:00  **POST-TRAUMATIC HEADACHE**  
Chair: M. Linde – (Trondheim, Norway)  
Post-traumatic headache is a unique headache disorder – M. Linde (Trondheim, Norway)  
Novel insight into post-traumatic headache – G. Ifergane (Omer, Israel)

10:00 - 11:00  **INDUSTRY SPONSORED SESSION - Non CME Session**

11:00 - 11:30  **COFFEE BREAK AND e-POSTER DISCUSSION**

11:30 - 13:00  **NEUROPHARMACOLOGY OF MIGRAINE**  
Chair: A. Maassen van den Brink (Rotterdam, The Netherlands)  
The CGRP family of peptides – L. Edvinsson (Lund, Sweden)  
Gender aspect of CGRP in migraine – A. Maassen van den Brink (Rotterdam, The Netherlands)  
Serotonin (triptans and ditans) & dopamine: mode of action (PET & clinical trials data) – U. Reuter (Berlin, Germany)  
Reproducibility of biochemical markers (neuropeptides, neurosteroids) in primary headache – P. Geppetti (Florence, Italy)

13:00 - 14:00  **BREAK & E-POSTER DISCUSSION**

14:00 - 15:00  **INDUSTRY SPONSORED SESSION - Non CME Session**

15:00 - 16:00  **EMERGING TARGETS FOR TREATMENT - APART FROM CGRP**  
Chair: S. Silberstein (Philadelphia, USA)  
Cannabinoids: endogenous and exogenous; hope or bluster? – S. Silberstein (Philadelphia, USA)  
PAC1, PACAP – A.L. Vollesen (Copenhagen, Denmark)  
$K_{ATP}$ channels – M. Al-Kharagholi (Copenhagen, Denmark)
Saturday, 29 September 2018

Auditorium

16:00 - 18:00  RE-READING BURNING TOPICS

Chairs: D.D. Mitsikostas (Athens, Greece), M. Braschinsky (Tartu, Estonia)

Placebo is a universal problem, it is just that expectation response in adults creates a window for small but significant therapeutic effect – D.D. Mitsikostas (Athens, Greece)

Novel views in Idiopathic Intracranial Hypertension – A. Sinclair (Birmingham, UK)

RCVS and cerebral vasculitis – A. Steinberg (Stockholm, Sweden)

Imaging in headache experimental research — F. Amin (Copenhagen, Denmark)

What have we learned from cellular and circuit mechanisms of the primary brain dysfunctions that cause familial hemiplegic migraine? – D. Pietrobon (Padua, Italy)

Manual approach to tension-type headache. Is this a reliable approach? – C. Fernández-de-Las-Peñas (Madrid, Spain)

Sala Verde

08:00 - 09:00  EHF-SCHOOL OF ADVANCED STUDIES

09:00 - 10:00  NEUROPHYSIOLOGY OF THE MIGRAINE BRAIN

Chair: Z. Katsarava (Unna, Germany)

The migraine brain is inheritably hyper-responsive – D. Magis (Liège, Belgium)

The migraine brain is not hyper-responsive – T. Sand (Thondheim, Norway)

10:00 - 11:00  ORAL PRESENTATIONS (N=6)

11:00 - 11:30  COFFEE BREAK AND e-POSTER DISCUSSION

11:30 - 13:00  ORAL PRESENTATIONS (N=9)

13:00 - 14:00  BREAK & e-POSTER DISCUSSION

14:00 - 15:00  INDUSTRY SPONSORED SESSION - Non CME Session

15:00 - 16:00  THE BLOOD BRAIN BARRIER

Chair: C. Ayata (Boston, USA)

The BBB opens up during migraine – C. Ayata (Boston, USA)

The BBB does not open during migraine – F. Amin (Copenhagen, Denmark)

16:00 - 17:00  EHF-SCHOOL OF ADVANCED STUDIES
09:00 - 10:00  TEACHING COURSE  
MIGRAINE AND HORMONES  
Chair: A. Maassen van den Brink (Rotterdam, The Netherlands)  
Hormonal contraceptives: how they impact on migraine course – S. Sacco (L'Aquila, Italy)  
Hormonal contraceptives in women with migraine: pros and cons – E.A. MacGregor (London, United Kingdom)  

10:00 - 11:00  TEACHING COURSE  
PRECISION MEDICINE IN COMPLEX MIGRAINE PATIENTS  
Chair: P. Martelletti (Rome, Italy)  
Precision Medicine general concept in clinical pratice – M. Simmaco (Rome, Italy)  
Metabolomics and Therapeutic Drug Monitoring: a routine tool – L. Lionetto (Rome, Italy)  
Three dimensional approach for DDI evaluation in Precision Medicine – P. Martelletti (Rome, Italy)  

11:00 - 11:30  COFFEE BREAK AND e-POSTER DISCUSSION  

11:30 - 13:00  TEACHING COURSE  
ARBORIZATIONS OF CORTICAL SPREADING DEPRESSION  
Chair: R. Burstein (Boston, USA)  
History of SD and migraine – M. Lauritzen (Glostrup, Denmark)  
Electrophysiological mechanisms of SD: from channels to extracellular potential shifts – D. Pietrobon (Padua, Italy)  
SD susceptibility as a drug screening tool – C. Ayata (Boston, USA)  
SD as a trigger for headache – R. Burstein (Boston, USA)  

13:00 - 14:00  BREAK & E-POSTER DISCUSSION  

14:00 - 15:00  TEACHING COURSE  
PERIPHERAL INTERVENTIONAL MANAGEMENT OF REFRACTORY HEADACHES  
Chair: G. Lambru (London, UK)  
Head and neck nerves blockade – A. Özge (Mersin, Turkey)  
Sphenopalatine ganglion and trigger points blockade – D. Uludüz (Istanbul, Turkey)  

15:00 - 16:00  EHF - IHS TEACHING COURSE  
THE BROAD SPECTRUM OF SECONDARY HEADACHES  
Chairs: M. Ashina (Copenhagen, Denmark), P. Martelletti (Rome, Italy)  
Sports and headache – R. Evans (Houston, USA)  
Headache attributed to non-vascular intracranial disorder – R. Jensen (Copenhagen, Denmark)  
Headaches associated with eye diseases – A. Sinclair (Birmingham, UK)  
Cluster headache-like – G. Lambru (London, UK)  

16:00 - 17:00  EHF-SCHOOL OF ADVANCED STUDIES
08:00 - 09:00  **SECONDARY HEADACHES**

**Chair**: C. Lampl (Linz, Austria)

The secondary headaches: a cul de sac for the headache expert? — C. Lampl (Linz, Austria)

Managing secondary headaches with a multimodal expertise – H. Schytz (Copenhagen, Denmark)

09:00 - 10:00  **EHF 2018 GUIDELINES ON MIGRAINE TREATMENT**

**Chair**: P. Martelletti (Rome, Italy)

EHF Guidelines on the use of CGRP(r) MAbs in migraine – S. Sacco (L’Aquila, Italy)

EHF Guidelines on the use of OnabotulinumtoxinA in migraine – L. Bendtsen (Copenhagen, Denmark)

10:00 - 11:00  **HEADACHE COST, HEADACHE CARE: FINDING BALANCE IN EUROPE**

**Chair**: T.J. Steiner (London, UK)

Counting cost: disability and lost productivity – T.J. Steiner (London, UK)


Providing care: migraine medication and a mishandled market: errors that undermine care – Z. Katsarava (Unna, Germany)

11:00 - 11:30  **COFFEE BREAK AND e-POSTER DISCUSSION**

11:30 - 12:30  **CLUSTER HEADACHE: WHO IS THE CULPRIT?**

**Chair**: K. Paemeleire (Ghent, Belgium)

Do we have new approaches to cluster headache? – K. Paemeleire (Ghent, Belgium)

Do we treat cluster headache correctly? – M. Matharu (London, UK)

12:30 - 13:30  **CLOSING**

**Chairs**: P. Martelletti, R. Burstein, D.D. Mitsikostas

EHF-SAS 2018 Fellowship Awards

EHF Athens 2019 Congress Presentation
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td><strong>EHF - SCHOOL OF ADVANCED STUDIES</strong></td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td><strong>ORAL PRESENTATIONS (N=6)</strong></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td><strong>COFFEE BREAK AND e-POSTER DISCUSSION</strong></td>
</tr>
<tr>
<td>11:30 - 13:00</td>
<td><strong>ORAL PRESENTATIONS (N=9)</strong></td>
</tr>
</tbody>
</table>
9:00 - 10:30

01 - New pharmacology, expression profiles and probes of CGRP receptors - Debbie Hay

02 - Efficacy, Safety, and Tolerability of Orally Administered Atogepant for the Prevention of Episodic Migraine: Results from a Phase 2b/3 Study - Peter J. Goadsby, David W. Dodick, Joel M. Trugman, Michelle Finnegan, Hassan Lakiss, Kaifeng Lu, Armin Szegedi

03 - Alterations in CGRP and PACAP38 levels in cluster headache - Agneta Snoer, Anne Luise Haulund Vollesen, Rasmus Paulin Beske, Song Guo, Jan Hoffmann, Jan Fahrenkrug, Niklas Rye Jørgensen, Torben Martinussen, Rigmor Højland Jensen, Messoud Ashina

04 - Medication overuse in a post-hoc analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine - Sheena K Aurora, Paula A Morrow, Dustin D Ruff, Eric Pearlman

05 - Study CGAL: a placebo-controlled study of galcanezumab in patients with episodic cluster headache: results from the 8-week double-blind treatment phase - James M. Martinez, Peter J. Goadsby, David Dodick, Jennifer N. Bardos, Tina M. Myers Oakes, Brian A. Millen, Chunmei Zhou, Sherie A. Dowsett, Sheena K. Aurora, Jyun Yan Yang, Robert R. Conley, Massimo Leone

011 - Migraine induction with calcitonin gene-related peptide in patients from erenumab trials - Casper Emil Christensen, Samaira Younis, Marie Deen, Sabrina Khan, Hashmat Ghanizada, Messoud Ashina

017 - Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low- versus high-frequency of migraine headaches - Virginia L Stauffer, Stephen Silberstein, Virginia L Stauffer, Katie Day, Qi Zhang, Sarah Lipsius, Maria Carmen Wilson

018 - Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies - Qi Zhang, Sheena K. Aurora, Qi Zhang, Virginia L. Stauffer

019 - Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2 and REGAIN studies - Apeksha Rao, Grazia Dell’Agnello (Presenter), Antje Tochhorn-Heidenreich, Qi Zhang, Dustin D. Ruff, Eric M. Pearlman, Sheena K. Aurora, Janet H. Ford
031 - Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine - Virginia Stauffer, Kathleen A. Day, Michael Ament, Virginia L. Stauffer, Vladimir Skljarevski, Qi Zhang, Eric M. Pearlman, Sheena K. Aurora

032 - Factors associated with significant reduction in migraine headache days: a post hoc analysis of phase 3 placebo-controlled trials of patients with episodic and chronic migraine treated with galcanezumab - Qi Zhang, Sheena K. Aurora, Dustin D. Ruff, Qi Zhang, Eric M. Pearlman

033 - Effect of galcanezumab on possible menstrual-related migraine: exploratory analyses results from EVOLVE-1, EVOLVE-2 and REGAIN - Sheena Aurora, Maria S. Fernandes, Holland C. Detke, Qi Zhang, Elena M. Pavlovic, Sheena K. Aurora

038 - Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication - Paul K. Winner, Rashmi B. Halker Singh, Joshua M. Cohen, Ronghua Yang, Paul P. Yeung, Verena Ramirez Campos

039 - Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication - Stephen D. Silberstein, Jessica Ailani, Joshua M. Cohen, Ronghua Yang, Paul P. Yeung, Verena Ramirez Campos

040 - Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication - Peter McAllister, David W. Dodick, Joshua M. Cohen, Ronghua Yang, Paul P. Yeung, Verena Ramirez Campos
ORAL PRESENTATION / CHAIR: Kirill Skorobogatykh

SALA VERDE

10:00 - 11:00


07 - Ten factors associated to migraine chronification: a cross-sectional study on 318 long-term migraine sufferers - Michele Viana, Sara Bottiroli, Grazia Sances, Giuseppe Nappi, Cristina Tassorelli

09 - White matter microstructure changes in migraine: a diffusional kurtosis imaging study - Sait Ashina, Bettina Conti, Benjamin Ades-Aron, Yvonne Lui, Mia Minen, Dmitry Novikov, Timothy Shepherd, and Els Fieremans

10 - Meningeal contribution to migraine pain: a 3T magnetic resonance angiography study - Sabrina Khan, Faisal Mohammad Amin, Casper Emil Christensen, Hashmat Ghanizada, Samaira Younis, Anne Christine Rye Andersen, Patrick J H de Koning, Henrik B W Larsson, Messoud Ashina

12 - Incidence, clinical characteristics and long-term course of headache in patients with stroke (DMKG multicenter study) - Thomas Dresler, Sarah Dietrich, Andrea Düring, Daniel Rothkirch, Filipp Filippopulos, Ozan Eren, Andre-as Straube, Stephan Zierz, Gudrun Goßrau, Torsten Kraya

13 - Headache in transient ischemic attacks - Elena Lebedeva, Natalia M. Gurary, Jes Olesen
026 - Searching for a neural signature of hallodynia in migraine: a volumetric MRI study - Francesca Pistoia, Claudia Marsecano, Antonio Carolei, Riccardo Cornia, Luana Evangelista, Alessandra Splendiani, Simona Sacco

027 - Dopaminergic symptoms in migraine: a case series on 1148 patients - P. Barbanti, P. Ferroni, G. Egeo, L. Fofi, C. Aurilia

030 - Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy - Kerry Knievel, Louise Lombard, Andrew Buchanan, Simin Baygani, Joel Raskin, Joshua Tobin

034 - Primary angiitis of the central nervous system and reversible cerebral vasoconstriction syndrome. A comparative study of two cohorts - Hubert de Boysson, Jean-Jacques Parienti, Jérôme Mawet, Caroline Arquizan, Grégoire Boullouis, Cécilia Burcin, Olivier Naggar, Mathieu Zuber, Emmanuel Touzé, Achille Aouba, Marie-Germaine Bousser, Christian Pagnoux, Anne Ducros


036 - Migraine progression in natural subgroups of migraine based on comorbidities and concomitant conditions: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study - Richard B. Lipton, Vincent T. Martin, Michael L. Reed, Cristina M. Fanning, Aubrey Manack Adams, Dawn C. Buse

037 - Complete detoxification is the most feasible treatment for medication-overuse headache: A randomized controlled open-label trial - Ida M S Engelstoft, Louise N Carlsen, Signe B Munksgaard, Mia Nielsen, Rigmor H Jensen, Lars Bendtsen

041 - Cluster headache is not associated with sleep apnea or specific sleep stages - N. Lund, M. Barloese, A. Snoer, A. Petersen, P. Jørgen Jennum, R.H.Jensen

10:00 - 11:00


**014** - Optimization of vagues nerve stimulation efficacy on cortical spreading depression - Andreia Morais, Andreia Lopes de Morais, Tsubasa Takizawa, Inge Mulder, Tao Qin, BS1, Bruce Simon, Rubem Carlos Araujo Guedes, Cenk Ayata

**015** - DNA methylation pattern of CALCA gene in patients with migraine - Elisa Rubino, Silvia Boschi, Alessandro Vacca, Salvatore Gentile, Lorenzo Pinessi, Maria Teresa Giordana, Innocenzo Rainero

**020** - Cephalic and extracephalic neurophysiological effects of botulinum toxin type A treatment in chronic migraine - Gianluca Coppola, Francesca Cortese, Davide Di Lenola, Cherubino Di Lorenzo, Vincenzo Parisi, Francesco Pierelli.


**022** - Long-term outcomes after reversible cerebral vasoconstriction syndrome: recurrence, cardiovascular events and mortality in a prospective follow-up study - Rosalie Boitet, Solène De Gaalon, Grégory Marin, Claire Duflos, Caroline Roos, Jérôme Mawet, Cécilia Burcin, Ursula Fiedler, Marie-Germaine Bousser et Anne Ducros
11:30 - 13:00

016 - The impact of chronic headache on workdays, unemployment and disutility in the general population - Espen Saxhaug Kristoffersen, Knut Stavem, Christofer Lundqvist, Michael Bjørn Russell

023 - Complete detoxification is the most effective in reducing disability in patients with medication-overuse headache: A randomized controlled open-label trial - Louise Carlsen, Mia Nielsen, Louise N Carlsen, Rigmor H Jensen, Signe B Munksgaard, Ida M S Engelstoft, Lars Bendtsen

024 - The economic and humanistic burden of episodic and chronic migraine in Europe - Hicham Benhaddi, Timothy Fitzgerald, Sophie McCabe, Ruth Zeidman

025 - Headache outcome measures in medically refractory chronic migraine patients treated with OnabotulinumtoxinA - Manjit Matharu, Lagrata Susie, Ahmed Maha, Miller Sarah, Matharu Manjit

028 - Non-invasive vagus nerve stimulation (nVNS) for the acute treatment of episodic migraine: additional findings from the randomised, sham-controlled, double-blind PRESTO trial - Eric Liebler, Paolo Martelletti; Licia Grazzi; Giulia Pierangeli; Innocenzo Rainero; Pierangelo Geppetti; Anna Ambrosini; Paola Sarchielli; Piero Barbanti; Cristina Tassorelli; Eric Liebler; Marina de Tommaso

029 - Tocilizumab in patients with giant cell arteritis: results from a Phase 3 randomized controlled trial - Susan Mollan, Katie Tuckwell, Sophie Dimonaco, Micki Klearman, Neil Collinson, John H Stone


043 - Effect of the H1-antihistamine clemastine on PACAP38 induced migraine - Anne Luise Haulund Vollesen,

045 - The practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) as an acute treatment for episodic migraine: a post hoc analysis of the randomised sham-controlled PRESTO trial - Eric Liebler, Licia Grazzi; Cristina Tassorelli; Marina de Tommaso; Giulia Pierangeli; Paolo Martelletti; Innocenzo Rainero; Pierangelo Geppetti; Anna Ambrosini; Paola Sarchielli; Eric Liebler; Piero Barbanti
SCREEN A

10:30 - 11:00

P1 - The cost of migraine in Greece: a half billion euros disease - Maria Kalogeropoulou, Panagiotis Stafyla, Marianthi Karaiskou, Eirini Tsiamaki, Maria Kalogeropoulou, Dimos-Dimitrios Mitsikostas

P2 - Single-pulse transcranial magnetic stimulation (sTMS) for the treatment of migraine: a prospective real world experience - Giorgio Lambru, Hill Bethany, Lloyd Joseph, Al Kaisy Adnan, Andreou Anna P

P3 - The impact of fremanezumab on symptoms associated with migraine in patients with episodic migraine - Jan Brandes, Jan L. Brandes, Paul P. Yeung, Ernesto Aycardi, Ronghua Yang, Yuju Ma, Joshua M. Cohen

P4 - The impact of fremanezumab on symptoms associated with migraine in patients with chronic migraine - Peter McAllister, Paul P. Yeung, Ernesto Aycardi, Ronghua Yang, Yuju Ma, Joshua M. Cohen

P5 - Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: interim results of a 1-year study - Jan Brandes, Paul P. Yeung, Joshua M. Cohen, Sanjay K. Gandhi, Timothy Fitzgerald, Ronghua Yang, Yuju Ma, Ernesto Aycardi

SCREEN B

10:30 - 11:00

P6 - Overview of fremanezumab pooled safety data from placebo-controlled phase 2 and 3 studies - Stephen D. Silberstein, Nicola Faulhaber, Xiaoping Ning, Paul P. Yeung, Jimmy Schiemann, Ronghua Yang, Yuju Ma, Ernesto Aycardi

P7 - Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment - Joshua M. Cohen, Kristen Bibeau, Maja Galic, Michael J. Seminerio, Verena Ramirez Campos, Rashmi B. Halker Singh, Jessica Allani

P8 - Efficacy of fremanezumab in patients with chronic migraine with or without concomitant use of preventive medication - Peter J. Goadsby, David W. Dodick, Stephen D. Silberstein, Paul P. Yeung, Tricia Blankenbiller, Xiaoping Ning, Ronghua Yang, Yuju Ma, Ernesto Aycardi, Marcelo E. Bigal

P9 - The Effect of Cognitive Behavioural Therapy on Self-Efficacy and Headache Frequency, in Chronic Migraine - Özlem Mercan, Ayhan Bingöl, Derya Uludüz, Özlem Mercan, Yasemin Akinci, Duygu Deringöl, Sabahattin Saip, Aksel Siva
SCREEN B

10:30 - 11:00  P10 - Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression - Joshua M. Cohen, Paul P. Yeung, Ernesto Aycardi, Marcelo E. Bigal, Ronghua Yang, Kristen Bibeau, Maja Galic, Michael J. Seminerio, Richard B. Lipton, Dawn C. Buse

SCREEN C

10:30 - 11:00  P11 - Achievement of response over time with fremanezumab in the treatment of chronic and episodic migraine - Stephen D. Silberstein, Richard B. Lipton, Merle L. Diamond; Joshua M. Cohen, Ronghua Yang, Bo Jiang

P12 - The impact of fremanezumab on medication overuse in patients with chronic migraine - Stephen D. Silberstein, Sait Ashina, Zaza Katsarava, Kristen Bibeau, Michael J. Seminerio, Danielle E. Harlow, Joshua M. Cohen

P13 - Work productivity amongst those with migraine: results from the My Migraine Voice survey - Todd J. Schwedt, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Michel Lanteri-Minet, Hans-Christoph Diener, Annik K.-Laflamme, Elena Ruiz de la Torre, Audrey Craven, Annette Vangaa Rasmussen, Donna Walsh, Simon Evans, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo

P14 - Headache following mild traumatic brain injury (MTBI) in a population-based, controlled, longitudinal study - Lena Hoem Nordhaug

P15 - A randomised, double-blind, placebo-controlled study of erenumab safety in patients with stable angina - Christophe Depre, Lubomir Antalik, Amaal Starling, Michael Koren, Osaro Eisele, Daniel D Mikol

SCREEN D

10:30 - 11:00  P16 - Burden and patient-reported outcomes of migraine patients with prior prophylactic treatment failure: Study design of the multinational BECOME study - Paolo Martelletti, Christian Lucas, Patricia Pozo-Rosich, David Watson, Charly Gaul, Emma Ramsden, Shannon Ritter, Josefin Snellman

P17 - My Migraine Voice: a worldwide survey of 11,266 migraine patients - Elena Ruiz de la Torre, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Todd J. Schwedt, Michel Lanteri-Minet, Hans-Christoph Diener, Annik K.-Laflamme, Annette Vangaa Rasmussen, Donna Walsh, Audrey Craven, Simon Evans, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo
e-POSTER DISCUSSION / DISCUSSANT: Willem Sebastian Van Hoogstraten

SCREEN D
10:30 - 11:00

**P18** - Economic burden of migraine: healthcare resource utilization in the My Migraine Voice survey - Paolo Martelletti, Rebeca Quintana, Veruska Carboni, Todd J. Schwedt, Michel Lanteri-Minet, Hans Christoph Diener, Annik K. Laflamme, Elena Ruiz de la Torre, Audrey Craven, Simon Evans, Donna Walsh, Annette Vangaa Rasmussen, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo

**P19** - Effect of galcanezumab following double-blind treatment in patients with migraine: results from EVOLVE-1 and EVOLVE-2 - Virginia Stauffer, Qi Zhang, Paula A. Morrow, Virginia L Stauffer, Vladimir Skljarevski, Eric M. Pearlman, Sheena K Aurora

**P20** - Sustained efficacy over 1 year of treatment with erenumab: Results from the extension phase of the STRIVE study in episodic migraine - Peter J Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo H Bonner, Feng Zhang, Sandhya Sapra, Denise E Chou, Jan Klatt, Hernan Picard, Robert A Lenz, Daniel D Mikol

SCREEN E
10:30 - 11:00

**P21** - Efficacy outcomes in responder and nonresponder patients with episodic migraine treated preventively with erenumab in the STRIVE study - Gregor Brössner, Uwe Reuter, Jo H Bonner, David W Dodick, Hernan Picard, Shihua Wen, Shannon Ritter, Jan Klatt, Daniel D Mikol

**P22** - Efficacy of erenumab in patients with chronic migraine achieving ≥50% response: Subgroup analysis of a double-blind, randomised study - David Dolezil, Jan Klatt, Sunfa Cheng, Feng Zhang, Shihua Wen, Shannon Ritter, Daniel D Mikol

**P23** - Long-term safety and tolerability of erenumab: Three-plus year results from an ongoing open-label extension study in episodic migraine - Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen Silberstein, David Dodick, Gregory A. Rippon, Jan Klatt, Feng Zhang, Sunfa Cheng, Daniel D. Mikol

**P24** - Assessment of the long-term safety and efficacy of erenumab during open-label treatment of subjects with chronic migraine - Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Feng Zhang, Sunfa Cheng, Daniel Mikol

**P25** - Immunogenicity findings from Phase 3 galcanezumab trials in patients with episodic or chronic migraine - James M. Martinez, Sandra Garces, Greg Anglin, Michael Hodsdon, William Kielbasa, Brian A Moser, Eric Pearlman
SCREEN A

13:00 - 14:00


**P27** - Effect of OnabotulinumtoxinA on the Frequency and Impact of Headaches in Patients with Chronic Migraine with or without a History of Acute Pain Medication Overuse: Results of the COMPEL Study - Stewart J. Tepper, MD, Maria-Carmen Wilson, MD, John F. Rothrock, MD, Amelia Orejudos, MsC, Aubrey Manack Adams, PhD, Andrew M. Blumenfeld, MD,

**P28** - Body Mass Index and its relationship with disability, severity, duration and frequency of headaches in female migraine patients - Faraidoon Hagdooost, Mansouerh Toigha, Faraidoon Hagdooost, Faezeh Khorsa, Soodeh Razeghi Jahromi, Zeinab Ghorbani


**P30** - Effects of subthreshold single pulse Transcranial Magnetic Stimulation (sTMS on activity of hypothalamic A11 region - Joseph Lloyd, Dr M Jones, Prof S McMahon, R Abuukar Abdullahi, Dr AP Andreou


**P32** - Triptans use in post-dural puncture headache - Federico Mainardi, Giorgio Zanchin, Carlo Lisotto, Ferdinando Maggioni

**P33** - A case of autoimmune encephalitis preceded by posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome - Jaeho Kim, Mi Ji Lee

**P34** - New insights in post-traumatic cluster headache through a cohort study - Grangeon Lou, Lou Grangeon, Emer O’Connor, Layan Akijian, Thanh Mai Pham, Manjit Matharu
e-POSTER DISCUSSION / DISCUSSANT: Alejandro Labastida Ramirez

SCREEN A

13:00 - 14:00  
P35 - The relevance of associated symptoms of migraine according to migraine subtypes: A Clinical study - Osman Özgür Yalın, Aynur Özge, Osman Özgür Yalın, Derya Uludüz, Özlem Mercan, Mehmet Ali Sungur, Aksel Siva

SCREEN B

13:00 - 14:00  
P36 - Descriptive analysis of a population with chronic migraine in a tertiary Headache Center - Luzeiro Isabel, Ana-Inês Martins, Joana Ramos-Lopes, Pedro Lopes, Bruno Silva, Sónia Batista, Lívia Sousa, Isabel Luzeiro

P37 - White matter lesions in chronic Migraine are related with molecular markers of inflammation and blood brain barrier disruption - Clara Domínguez Vivero, C. Domínguez, M. Saavedra, X. Rodríguez-Osorio, T. Sobrino, F Campos, J. Castillo, R. Leira


P39 - Economic impact of migraine in the EU5: a matched analysis of the NHWS 2017 data on work productivity and healthcare resource use - Pamela Vo, Michael J. Doane, Pamela Vo, Aikaterini Bilitou, Juanzhi Fang, Annik K-Laflamme, Shaloo Gupta

P40 - Humanistic burden of migraine in the EU5: a matched analysis of the NHWS 2017 - Pamela Vo, Michael J. Doane, Pamela Vo, Aikaterini Bilitou, Juanzhi Fang, Annik K-Laflamme, Shaloo Gupta

P41 - Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine - Linda Wietecha, Linda A. Wietecha, Bernice Kuca, Josephine Asafu-Adjéi, Sheena K. Aurora

P42 - Conversion from chronic to episodic migraine with erenumab, a specific inhibitor of the calcitonin gene-related peptide receptor - Richard B Lipton, Stewart J Tepper, Stephen Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David Dodick, Feng Zhang, Gregory A Rippon, Daniel D Mikol

P43 - Erenumab impact on patient-reported outcomes in chronic migraine in the presence of acute medication overuse - Stewart J Tepper, Messoud Ashina, Jan Klatt, Pooja Desai, Feng Zhang, Sunfa Cheng, Daniel D Mikol
SCREEN B

13:00 - 14:00

P44 - Long-term efficacy of erenumab in patients with chronic migraine who failed prior prophylactic treatment - Messoud Ashina, Stewart J. Tepper, Jan L. Brandes, Uwe Reuter, Guy Boudreau, David Doležil, Jan Klatt, Feng Zhang, Sunfa Cheng, Daniel D Mikol

P45 - Changes in patient functioning and disability: results from two phase 3 double blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2) - Jeffrey Carter, Janet H. Ford, David W. Ayer, Qi Zhang, Jeffrey N. Carter, Vladimir Skljarevski, Sheena K. Aurora

SCREEN C

13:00 - 14:00

P46 - 100% response rate to galcanezumab in patients with episodic migraine: randomized, double-blind, placebo-controlled studies - Eric Pearlman, Abraham Jim Nagy; Eric Pearlman; Dustin Ruff; Kathleen Day; Noah Rosen

P47 - Diagnostic screeners for migraine: a methodological caveat - Csaba Ertsey, Csépány É, Magyar M, Gyüre T, Bozsik Gy, Tóth M

P48 - Comparison of personality traits and dependence behavior between MOH patients and illicit drug users - Carlo Baraldi, Pellesi Lanfranco, Guerzoni Simona, Cainazzo Maria Michela, Lo Castro Flavia, Pini Luigi Alberto

P49 - Validity and reliability Turkish Headache Impact Test (HIT-6) in patients with episodic and chronic migraine - Pınar Yalinay Dikmen, P Yalinay Dikmen, M Bozdag, M Gunes, S Kosak, B Tasdelen, D Uludüz, A Özge

P50 - Retrospective analysis of peripheral nerve block for the treatment of headaches and cranial neuralgias in the neurology section of a general hospital - Vanesa Adell, Jessica García-Alhama, Sonia Jaraba, Joan Prat, Mariano Huerta

P51 - Relationship between severity of migraine and Vitamin D deficiency: a case control study - Laura Rapisarda, A.D. Montisano, A. Sarica, G. Demonte, F. Tosto, A. Gambardella, F. Bono

P52 - A case-control study of visual-vestibular mismatch in childhood with primary headaches - Carlo Baraldi, Daniele Monzani, Pellesi Lanfranco, Guerzoni Simona, Cainazzo Maria Michela, Lo Castro Flavia, Baraldi Carlo, Pini L Alberto
SCREEN C

13:00 - 14:00

P53 - Primary headaches associated with physical exertion - Füsun Mayda Domaç, Sergül Zengin, Mehmet Fatih Demir

P54 - Headache burden in the Emergency Room - Aida Quka, A. Quka, O. Cibuku, I. Zekja, I. Xhura, J. Kruja

P55 - Prevalence and risk factors of tension-type headache among adolescents in Kharkiv city (Ukraine) - Kostiantyn Stepanchenko

SCREEN D

P56 - Pediatric migraine: A new pediatric migraine-specific comorbidity index on prognosis - Osman Ozgur Yalin, Didem Derici Yildirim, Bahar Tasdelen, Derya Uluduz, Aynur Ozge, Osman Ozgur Yalin, Saim Yologlu


P59 - Vestibular Migraine presenting as an acute peripheral vestibulopathy: clinical and vestibular function test profiles - Zeljka Calic, Rachael L Taylor, Allison Young, Leigh M McGarvie, Cecilia Cappelen-Smith, Denis Cordato, Miriam S Welgampola

P60 - Headache in the Pediatric Emergency Department: proposal of diagnostic and therapeutic algorithm of management - Roberta Rossi, Antonia Versace, Barbara Lauria, Giulia Grasso, Emanuele Castagno, Fulvio Ricceri, Rosaura Pagliero, Antonio Francesco Urbino

P61 - Correlation between pediatric primary headache and specific learning disabilities: a case-control study - Antonia Versace, Ausilia Enea, Antonia Versace, Barbara Lauria, Giulia Grasso, Roberta Rossi, Emanuele Castagno, Stefania Benetti, Veronica Sciannameo, Antonio Francesco Urbino
**SCREEN D**

**13:00 - 14:00**

**P62** - Astrocytes contribute to the trigeminal central sensitization and cephalic cutaneous hypersensitivity in rat model of chronic migraine - M. Megemont, A. Descheemaeker, R. Dallel, L. Monconduit and P. Luccarini

**P64** - Cortical excitability in chronic migraine patients after OnabotulinumtoxinA preventive treatment - Vladlena Shevchenko, Ada Artemenko, Mikhail Bzhiljanski, Fedor Bushkov, Nikolay Yahno, Alexey Kurenkov

**P65** - Beyond the headache phase of a migraine attack: closer look at the burden of migraine phases – results from the worldwide My Migraine Voice survey - Michel Lanteri Minet, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Todd J. Schwedt, Hans Christoph Diener, Annik K.-Laflamme, Elena Ruiz de la Torre, Audrey Craven, Simon Evans, Donna Walsh, Annette VanGaal Rasmussen, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo

**SCREEN E**

**13:00 - 14:00**

**P68** - Demographic and clinical characteristics of patients with trigeminal neuralgia assisted by neurologists in an Emergency Department - Javier Camiña Muñiz, Germán Ferrer Juan, María Magdalena Rosselló Vadell, Antonio José Moreno Rojas, Francisco José Molina Martínez

**P69** - Systematic review of the safety and efficacy of Occipital Nerve Stimulation for intractable chronic cluster headache - Tinsley Jennifer, Iris Smet, Jean-Pierre Van Buyten, Michel Lanteri-Minet, Denys Fontaine, Jennifer Tinsley, Brooke Kelley
P70 - Safety data from phase 3 clinical studies comparing galcanezumab and placebo in patients with episodic and chronic migraine - Jeffrey Carter, Virginia L. Stauffer, Shufang Wang, Mark E. Bangs, Tina M. Oakes, Jeffrey N. Carter, Sheena K. Aurora


P72 - The role of foods with a high glycemic index in migraine patients: a real life preliminary study - Gianluca Cecchi, Gianluca Cecchi, Maria Bravo, Paola Di Caprio, Giorgia Botti, Nicoletta Brunelli, Matteo Paolucci, Manon Khazrai, Fabrizio Vernieri and Claudia Altamura

P73 - Do evidence-based practice guidelines exist to support physiotherapists in the approach of patients with episodic headache? - Sarah Mingels and Marita Granitzer

P74 - Efficacy and safety of a sequential surgical algorithm in 44 patients with refractory chronic cluster headache - Robert Belvís, Marina Guasch, Paula Marrero, Maria Jesus Alvarez, Rodrigo Rodríguez, Joan Molet, Carles Roig

P75 - Spectral domain optical coherence tomography findings in RVCL-S, a monogenic vascular migraine model - Irene de Boer, Sylvie R. Steenmeijer, Nadine Pelzer, Greet Dijkman, Irene C. Notting, Gisela M. Terwindt

P130 - Efficient therapy for treatment of migraine without aura: ergotamine based drugs or sumatriptan - Sinisa Miljkovic, Dz. Smajlovic, S. Crncevic, T. Jurisic, M. Tiric Campara, L. Duranovic Vinkovic, Z. Dostovic, Z. Pasic
SCREEN A

11:00 - 11:30  
P76 - Life traumatic experiences and stressful events as predictors of detoxification therapy outcome at 6 months in chronic migraine with medication overuse - Sara Bottiroli, Bottiroli Sara, Sances Grazia, De Icco Roberto, Vito Bitetto, Guaschino Elena, Marta Allena, Pazzi Stefania, Giuseppe Nappi & Tassorelli Cristina

P77 - Role of transient receptor potential (TRP) channels in a rat model of trigeminal neuropathic pain: focus on TRPA1 channels - Chiara Demartini, Rosaria Greco, Anna Maria Zanaboni, Oscar Francesconi, Cristina Nativi, Cristina Tassorelli, Kristof Deseure

P78 - Meningeal contribution to migraine pain: a 3T magnetic resonance angiography study - Sabrina Khan, Faisal Mohammad Amin, Casper Emil Christensen, Hashmat Ghanizada, Samaira Younis, Anne Christine Rye Andersen, Patrick J H de Koning, Henrik B W Larsson, Messoud Ashina

P79 - Sex differences in vascular responses to CGRP - Alejandro Labastida-Ramírez, Eloísa Rubio-Beltrán, A. van den Bogaerdt, J. Schouten, A.H. Jan Danser, Carlos M. Villalón & Antoinette Maassen van den Brink

P80 - Effect of onabotulinumtoxinA prevention on comorbidities of depression and anxiety in chronic migraine: Analysis in headache day frequency responders vs headache day frequency non-responders - Andrew Blumenfeld, Stewart J. Tepper, Lawrence D. Robbins, Amelia Orejudos, Aubrey Manack Adams, Dawn C. Buse, Stephen D. Silberstein

SCREEN B

11:00 - 11:30  
P81 - Life with migraine, effect on relationships, career and finances, and overall health and well-being: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study - Dawn C. Buse, Sharron Murray, Paula K. Dumas, Aubrey Manack Adams, Michael L. Reed, Kristina M. Fanning, Richard B. Lipton

P82 - A multicenter, prospective, randomized, open-label study to compare onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine: patient reported functional outcomes from the FORWARD study - Andrew M. Blumenfeld, Atul T. Patel, Aubrey Manack Adams, John F. Rothrock
29 September 2018

**e-POSTER DISCUSSION / DISCUSSANT: David Garcia Azorin**

**SCREEN B**

11:00 - 11:30  **P83** - Headache attributed to psychiatric disorder - Ana LJ Podgorac, Goran Gajic, Bojana Pejuškovic, Ljubica Zamurovic-Dunderovic, Vanja B Mandic-Maravic, Aleksandar Misojcic, Dušica M Lecic-Toševski

**P84** - Healthcare expenditure: does society give migraine the focus and recognition patients deserve? - Parth Joshi, Leonhard Schaetz, Parth Joshi, Aoife Callan, Vivek Khurana, Jasper Huels

**P85** - Gender differences in clinical and pharmacological response to triptans - Daphne S. van Casteren (in case the oral abstract is rejected), Tobias Kurth, Michel D. Ferrari, Gisela M. Terwindt, Antoinette Maassen van den Brink

**SCREEN C**

11:00 - 11:30  **P86** - Migraine induction with calcitonin gene-related peptide in patients from erenumab trials - Samaira Younis, Casper Emil Christensen, Samaira Younis, Marie Deen, Sabrina Khan, Hashmat Ghanizada, Messoud Ashina

**P87** - Mitochondrial DNA and migraine - Sigrid Børte, Bendik S. Winswold, Lars G. Fritsche, Ida Surakka, Jonas B. Nielsen, Wei Zhou, Cris Pen Willer and John-Anker Zwart

**P88** - Headache in Call Center Employees: an Occupational Disease - Jera Kruja, Ilir Alimehmeti, Xhovana Kane, Jera Kruja

**P90** - Psychosocial risk factors for headache - M Zalatel, L Zalatel-Kragelj, B Žvan
e-POSTER DISCUSSION / DISCUSSANT: David Garcia Azorin

SCREEN D

11:00 - 11:30

**P91** - The prevalence and some risk factors chronic headache in Mongolia - Selenge Enkhtuya, Otgonbayar Luvsannorov, Byambasuren Tsendedorj, Timothy J Steiner

**P92** - Symptoms of dependence in medication overuse headache: daily consumption versus days without consumption - Azimova J, Skorobogatykh K, Amelin A

**P93** - Effectiveness and safety of OnabotulinumtoxinA in the treatment of chronic migraine in patients older than 65 - María Castañón, E. Ameijide, J.M. Sánchez


**P95** - Non-compliance with follow-up: analysis of two years attendance to a second level headache centre in Italy - Teresa Catarci, Isabella Falomi and Roberto Batistoni

SCREEN E

11:00 - 11:30


**P98** - Effectiveness of OnabotulinumtoxinA in chronic migraine. If early introduction: faster, cheaper and more satisfactory - Robert Belvis, Noemí Morollón, Marina Guasch, Paula Marrero, Azahara Aceituno, Carles Roig

**P99** - Sickness absence and disability pension in cluster headache patients and in matched references: a population-based study - Anna Steinberg, Pontus Josefsson, Kristina Alexandersson, Christina Sjöstrand

**P100** - Clinical features of pediatric medication overuse headache and applicability of new ICHD-3 criteria - Romina Moavero, Maddalena Stornelli, Laura Papetti, Barbara Battan, Samuela Tarantino, Federico Vigevano, Massimiliano Valeriani
e-POSTER DISCUSSION / DISCUSSANT: Zoe Delaruelle

SCREEN A

13:00 - 14:00

P101 - C-tactile touch perception and habituation in migraineurs - Lapp Hanna Sophie, Ilona Croy, Gudrun Gossrau

P102 - Endeavor to identify associations between vaping and primary headaches - Marge Vaikjärv, Kati Toom, Mark Braschinsky

P103 - NDPH sub-categories and treatment in pediatrics patients - Priyanka Shekhawat

P104 - Frequency, referral and demographic characteristics of patients with vestibular migraine from a tertiary centre - Isabel Luzeiro

P105 - Migraine comorbidity and cognitive performance in patients with focal epilepsy - Olivia Begasse de Dhaem, Chris Morrison, Kimford J Meador, Dale E Hesdorffer, Sabrina Cristofaro, Jacqueline French, Mia T Minen, on behalf of the HEP Investigators

P106 - Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia - Mona Ameri Chalmer, Thomas Folkmann Hansen, Jes Olesen

P107 - Living with migraine: a report from the My Migraine Voice survey - Audrey Craven, Rebeca Quintana, Veruska Carboni, Paolo Martelletti, Michel Lanteri Minet, Todd J. Schwedt, Hans-Christoph Diener, Annik K-Laflamme, Annette Vangaa Rasmussen, Elena Ruiz de la Torre, Donna Walsh, Simon Evans, Paula Dumas, Rachel Fink, Angela Fiorin, Stephanie Ribbe, Pamela Vo

P108 - A model concept for assessing the cost-effectiveness of prophylactic migraine treatments - Ronan Mahon, Pamela Vo, Philip Cooney, Andrii Danyliv, Aikaterini Bilitou, Nagasuman Toram, Sreelatha Vadapalle, Jasper Huels, Farooq Maniyar, Peter J. Goadsby, Mark Sculpher

P109 - Relative efficacy of outpatient infusion therapy on pediatric patients with post concussive headaches - Sara Gould, Erin Mackenzie Katz, Carly Ann Cignetti

P110 - Movement disorders as positive motor aura symptoms during hemiplegic migraine attacks - Elisa De La Cruz, Geneviève Demarquay, Caroline Roos, Isabelle Sabatier, Florence Riant, Victoria Gonzàlez, Anne Ducros
P111 - Long-term response to onabotulinumtoxin A in chronic migraine: analysis of efficacy and tolerability in a series of 40 patients - García-Azorín D, Sierra A, Trigo J, Martínez-Pías E, Guerrero AL.

P112 - Acute and preventive treatment patterns and associated work productivity and activity impairment among patients with migraine in Germany - Jeffrey Scott Andrews, Janet Ford, Grazia Dell’Agnello, Sarah Cotton, Antje Tockhorn-Heidenreich, Louise Lombard, Zoe Phillips, James Jackson

P113 - Baseline demographics and disease characteristics of patients with episodic cluster headache: results from a phase 3 clinical trial - James M. Martinez, Jennifer N. Bardos, Tina M. Myers Oakes, Chunmei Zhou

P114 - PrevenBox: Evaluation of concomitant use of preventive medications with OnabotulinumtoxinA in migraine - Marta Torres-Ferrus, Sonia Santos Lasoasa; Angel Guerrero Peral; Jose M Lainez; Javier Viguera Romero; Ana B Gago Veiga; Pablo Irimia; Margarita Sanchez del Rio; Laila Asskour; Victor J Gallardo; Patricia Pozo-Rosich


P116 - New daily persistent headache: A systematic review on an enigmatic disorder - Nooshin Yamani, Jes Olesen

P117 - Clinical description of 135 patients with typical aura without headache and scale proposal for diagnosis in a first episode - Robert Belvis, Marina Guasch, Paula Marrero, Noemí Morollón, Azahara Aceituno, Carles Roig

P118 - Onabotulinumtoxin A for Chronic Migraine with Medication Overuse: Preliminary Clinical Results and Changes in Catastrophising - Licia Grazzi, Eleonora Grignani, Emanuela Sansone, Alberto Raggi, Matilde Leonardi, Domenico D’Amico, Frank Andrasik

P119 - Mindfulness meditation for migraine in pediatric population: a pilot study - Licia Grazzi, Emanuela Sansone, Raggi Alberto, Eleonora Grignani, Matilde Leonardi, Chiara Scaratti, Frank Andrasik

P120 - Prophylactic effect of ultramicronized N-Palmitoyl Ethanol Amide (PEA) on pediatric migraine: a preliminary study - Giorgia Sforza, Laura Papetti, Samuela Tarantino, Barbara Battan, Michela Ada Noris Ferilli, Romina Moavero, Federico Vigevano, Massimiliano Valeriani
13:00 - 14:00


**P123** - Anxiety, depression and alexithymia in young migraine patients: which relationship with body weight? - Samuela Tarantino, Alessandra di Stefano, Laura Papetti, Barbara Battan, Giorgia Sforza, Federico Vigevano, Simonetta Gentile, Massimiliano Valeriani

**P124** - Health care resource use, sick-leaves and comorbidities among migraine patients in occupational health care - Minna A. Korolainen, Samu Kurki, Iiro Toppila, Mariann Lassenius, Timo Purmonen and Markku Nissilä

**P125** - The Number of Active Trigger Points is Associated with Pain Features, Depression and Anxiety in Frequent Episodic, but not Chronic, Tension Type Headache - César Fernández-de-las-Peñas, Stella Fuensalida-Novó, María Palacios-Ceña, Matteo Castaldo, Kelun Wang, Lars Arendt-Nielsen

**P126** - New daily persistent headache in a pediatric population - Laura Papetti, Barbara Battan, Romina Moavero, Giorgia Sforza, Samuela Tarantino, Massimiliano Valeriani Headache Center Bambino Gesù Children Hospital, Rome Italy

**P127** - Cerebral vascular reactivity in patients with chronic neck pain - Nevzat Uzuner, Aycan Guner Ekici, Gulnur Tekgol Uzuner, Sacit Gulec

**P128** - Chronic migraine is much more related to cardiovascular risk factors: a clinic based study - Gulnur Tekgol Uzuner, Osman Ozgur Yalin, Derya Uluduz, Aynur Ozge, Nevzat Uzuner

**P129** - The “pure” Trochlear Migraine : two cases and nosographic considerations - vincenzo raieli, Luca Maria Messina, Francesca Cardella, Rosaria Roppolo, Francesca Vanadia, Filippo Brighina, Vincenzo Raieli
P131 - Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials - Apeksha Rao, Russell M. Nichols (Presenter); Dustin Ruff; Eric Pearlman; Sheena K. Aurora, MD


P133 - Migraine and cluster headache – the common link - Anne Luise Vollesen

P134 - Providing care: Cost-effective and affordable - Michela Tinelli

P135 - The Activity Impairment in Migraine – Diary (AIM-D): A novel migraine-specific patient-reported outcome measure to assess functioning based on activity impairment in episodic and chronic migraine patients - Monica Elmore, ML Cala, CA Graham, RB Lipton, N Lyn, DW Dodick, C Burk, JS Yu, CJ Evans, HN Viswanathan

P136 - Epidemiology of chronic and episodic migraine in Europe - Hicham Benhaddi, Timothy Fitzgerald, Sophie McCabe, Ruth Zeidman

P137 - The impact of offering monthly and quarterly dosing options for a new class of migraine preventive therapy on likelihood of acceptance and adherence in adults with migraine - Ravi Iyer, Robert Cowan, Joshua Cohen, Erik Rosenman, Tim Fitzgerald, Ravi Iyer

P138 - Prognosis of trigeminal neuralgia is very favourable when managed by specialists – a two-year prospective real-life study - Tone Heinskou, Tone Bruvik Heinskou, Stine Maarbjerg, Frauke Wolfram, Per Rochat, Jannick Brennum, Jes Olesen and Lars Bendtsen

P139 - Serum changes of apolipoproteins in Medication Overuse Headache (MOH) - Lanfranco Pellesi, Elisa Bellei, Carlo Baraldi, Flavia, Simona Guerzoni, Emanuela Monari, Luigi Alberto Pini

P140 - Robust association between Obstructive sleep apnea (OSA) and Idiopathic intracranial hypertension (IIH) in Chronic daily headache (CDH) - G. Demonte, L. Rapisarda, F. Tosto, F. Roccia, M. Sturniolo, A. Gambardella, F. Bono
29 September 2018

e-POSTER DISCUSSION / DISCUSSANT: Zoe Delaruelle

SCREEN E

13:00 - 14:00

**P141** - Loss of periventricular white matter microstructure integrity in idiopathic intracranial hypertension - Laura Rapisarda, Giulio Demonte, Federico Tosto, Maria Curcio, Alessia Sarica, Antonio Cerasa, Antonio Gambardella, Francesco Bono

**P142** - Quality of life in the active phase of cluster headache - Ertsey C, Dióssy M, Magyar M, Gyüre T, Csépány É, Bozsik Gy

**P143** - Self-detoxification from medication overuse reduces disability among patients with MOH - Espen Saxhaug Kristoffersen, Ragnhild Berling Grande, Kjersti Aaseth, Michael Bjørn Russell, Christofer Lundqvist

**P144** - Effects of non-invasive vagus nerve stimulation (nVNS) on resting-state EEG and laser-evoked potentials in migraine: findings from a subgroup of patients enrolled in the randomised, sham-controlled, double-blind PRESTO study - Eric Liebler, Eleonora Vecchio, legé Bassez, Katia Ricci, Cristina Tassorelli, Eric Liebler, Marina de Tommaso

**P145** - Migraine, thrombophilic alterations, and vascular disease: results from a case control study - Cinzia Cavestro, Diana Degan, Gianmatteo Micca, Raffaele Alo, Silvia Mandrino, Carlo Di Pietrantonj, Maria Cristina Frigeri, Francesca Pistoia, Filippo Molinari, Simona Sacco

**P146** - Healthcare Resource Utilisation in Patients Treated with OnabotulinumtoxinA for Chronic Migraine: The REPOSE study - Monica Elmore, Katja Kollewe, Angela Antonakakis, Katherine Sommer, Justin S. Yu

**P147** - Proposed new diagnostic criteria for chronic migraine - Mona Ameri Chalmer, Thomas Folkmann Hansen, Elena Lebedeva, David Dodick, Jes Olesen

**P148** - Safety and efficacy of cervical 10 kHz cervical spinal cord stimulation (SCS) for the management of refractory chronic migraine: a prospective, proof-of-concept open label study - Lambru Giorgio, Al-Kaisy Adnan, Palmisani Stefano, Carganillo Roy, Wesley Samuel, Pang David

**P157** - Efficacy and safety of external trigeminal neurostimulation with the Cefaly® device in chronic migraine: an open trial - Schoenen Jean, Marius Birlea

**P158** - Abortive home treatment of migraine with external trigeminal neurostimulation using the Cefaly® device: a pilot trial - Schoenen Jean, Joseph Mann
e-POSTER DISCUSSION / DISCUSSANT: Raffaele Ornello

SCREEN A

11:00 - 11:30  
P151 - A multicentre, double-blind, randomised, sham-controlled study of non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the PREMIUM trial - Eric Liebler, Hans-Christoph Diener; Peter J. Goadsby; Messoud Ashina; Mohammad Al-Mahdi Al-Karagholi; Alexandra Sinclair; Dimos Mitsikostas; Delphine Magis; Patricia Pozo-Rosich; Pablo Irimia Sieira; Miguel J.A. Lainez; Charly Gaul; Nicholas Silver; Jan Hoffmann; Eric Liebler; Michel D. Ferrari

P152 - Post hoc analysis of the effects of more frequent non-invasive vagus nerve stimulation (nVNS) for patients with chronic cluster headache from the PREVA trial - Charly Gaul; Eric Liebler; Candace McClure; Annelie Andersson; Andreas Straube


P154 - Habituation determined by algometry as a marker of response in Chronic Migraine - García-Azorín D, Ruiz-Piñero M, Sierra A, Martinez B, Guerrero Peral AL

P155 - Study on the phenotypic characterization of delayed alcohol induced headache: series of 1184 sufferers - García-Azorín D, Aparicio Cordero L, Sierra Mencía A, Guerrero Peral AL

SCREEN B

11:00 - 11:30  
P149 - Is pituitary screening necessary in cluster headache? - Lou Grangeon, Emer O’Connor, Daisuke Danno, Thanh Mai Pham Ngoc, Indran avaghanam, Manjit Matharu

P150 - The impact on physician prescribing of monthly and quarterly dosing options for a new class of migraine preventive therapy - Robert Cowan, Erik Rosenman, Tim Fitzgerald, Joshua Cohen, Ravi Iyer

P156 - Ibuprofen and not paracetamol as first line analgesic for acute migraine due to its interaction with TRPA1 in the cinnamaldehyde target engagement biomarker model - Dorien Bamps, Laura Macours, Linde Buntinx, Jan de Hoon

P160 - Prevalence and clinical profile of migraine with aura in a cohort of young patients with minor stroke: a retrospective analysis - Claudia Altamura, Angelo Cascio Rizzo, Matteo Paolucci, Nicoletta Brunelli, Gianluca Cecchi, Fabrizio Vernieri
The increase of subcutaneous abdominal and body fat is a characteristic associated to allodynia in migraineurs - Mínguez-Olaondo A, Romero S, Frühbeck G, Martínez-Vila E, Irinima P

Clinical profile of migraine with aura and patent foramen ovale: a retrospective analysis - Claudia Altamura, Nicoletta Brunelli, Gianluca Cecchi, Angelo Cascio Rizzo and Fabrizio Vernieri

The Association Between Low Carbohydrate Diet Score and Migraine - Mansoureh Togha, Soodeh Razeghi Jahromi, Zeinab Ghorbani, Mansoureh Togha, Azita Hekmatdoost, Faezeh Khorsha, Boshra Torkan, Nasim Rezaelmanesh

The expanding burden of Idiopathic Intracranial Hypertension - Susan P Mollan, Magda Aguiar, Felicity Evison, Emma Frew, Alexandra J Sinclair

The Number of Active and Latent Trigger Points is Associated with Restricted Cervical Range of motion in Tension Type Headache - César Fernández-de-las-Peñas, María Palacios-Ceña, Stella Fuensalida-Novo, Matteo Castaldo, Kelun Wang, Lars Arendt-Nielsen, César Fernández-de-las-Peñas


Headache in pharmacy: observational study of pharmacological habit of cephalalgic patient - Giorgio Dalla Volta, Giorgio Zanchin, Maria Pia Prudenzano, Lidia Savi

**SCREEN D**

**11:00 - 11:30**  


**SCREEN E**

**11:00 - 11:30**  
P171 - Chromig10: evolution of migraine after 10 years - Edoardo Caronna, E. Fonseca Hernández; VJ. Gallardo; JB. Gomez; A. Alpuente; M. Torres-Ferrús; P. Pozo-Rosich

P172 - Whole Grain Cereal Consumption reduces migraine related disability - Claudia Altamura, Gianluca Cecchi, Giorgia Botti, Maria Bravo, Paola Di Caprio, Nicoletta Brunelli, Matteo Paolucci, Manon Khazrai and Fabrizio Vernieri

P173 - The Association Between Dietary Tryptophan Intake and Migraine - Mansoureh Togha, Soodeh Razeghi Jahromi, Mansoureh Togha, Zeinab Ghorbani, Hossein Ansari, Azita Hekmatdoost, Faezeh Khorsa, Pedram Shirani, Morvarid Nourmohammadi

P174 - Serum Vitamin B12 and Methyl-malonic Acid Status in a group of Migraine Patients Compared to Healthy Controls: A Case-Control Study - Mansoureh Togha, Soodeh Razeghi Jahromi, Zeinab Ghorbani, Fahimeh Martami, Maryam Seifishahpar

P175 - Preliminary efficacy study in prophylaxes of episodic tension cephalal and hemicrania without aura using a combination of Magnesium, L-Triptofano, Boswellia Serrata Casperome®, Niacina, Riboflavina and Vitamin D compared with Amitriptiline - Luigi Balzano, B. Ciccone
The 12th European Headache Federation Congress, Florence, Italy, 28/09/2018 to 30/09/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. “Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international activities. “Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”